Article

Retinal cell transplants show promising results in study

Encouraging results were achieved in preliminary research of the transplantation of retinal cells in patients with blindness caused by retinitis pigmentosa and age-related macular degeneration, according to a report in the August issue of the American Journal of Ophthalmology.

Louisville, KY-Encouraging results were achieved in preliminary research of the transplantation of retinal cells in patients with blindness caused by retinitis pigmentosa (RP) and age-related macular degeneration (AMD), according to a report in the August issue of the American Journal of Ophthalmology.

Lead author, Norman D. Radtke, MD, PSC, University of Louisville, KY, and colleagues performed experimental transplants in 10 patients, six patients with RP and four with the dry form of AMD, in this FDA-monitored study.

Fetal retinal cells were implanted along with their attached retinal pigment epithelium, which nourishes the photoreceptor cells-the concept being that the new cells would grow to replace the damaged photoreceptor cells, connecting the patient's remaining retina.

Visual improvements were found during follow-up testing in seven of the 10 patients: three patients with RP and all four patients with AMD. Vision remained in the "legally blind" range, however, the gains in vision were significant.

"This clinical evidence shows the promise of our method to alter progressive vision loss due to incurable degenerative diseases of the retina," commented Dr. Radtke.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.